Previous 10 | Next 10 |
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal, CPA, CA, as the newest member of its executive team; Jagpal will serve as the company chi...
2024-02-09 08:15:17 ET More on InMed Pharmaceuticals Historical earnings data for InMed Pharmaceuticals Financial information for InMed Pharmaceuticals Read the full article on Seeking Alpha For further details see: InMed Pharmaceuticals announces appoint...
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced the appointment of Ms....
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, announced that CEO Eric A Adams will be participating in the upcoming Water Tower Research Fireside Chat Series. This month’s cha...
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - InMed Pharmaceuticals Inc . (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, will be participating in the Water T...
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today outlined key accomplishments from 2023 and provided key strategic priorities for 2024. “In 2023, we experienced significant...
Advancing INM-901 as a multimodal treatment option for Alzheimer's Disease Advancing INM-089 in the treatment of Age-related Macular Degeneration Actively seeking partnerships to advance INM-755 in Dermatology BayMedica subsidiary continues to focus on revenue growth and market expansion...
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, is reporting on the results of its 2023 annual general meeting. According to the report, during the meeting, which was held...
Vancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (" InMed " or the " Company "), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual g...
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced the launch of INM-089, a cannabinol (“CBN”) analog, to investigate its effects in the treatme...
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
Reported positive preclinical data in both its Alzheimer's and dry AMD programs Closed Fiscal Q3 with cash position of US$7.9 million Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a clinical stage pharma...
Shares of Pinterest, Inc (NYSE:PINS) rose sharply in today's pre-market trading following strong first-quarter earnings and upbeat second-quar...
Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply in today's pre-market trading following first-quarter results. Tesla posted weaker-than-expec...